Valuation: C4 Therapeutics, Inc.

Market Cap 356M 316M 293M 266M 499M 33.68B 508M 3.52B 1.38B 17.63B 1.33B 1.31B 56.23B P/E 2026 *
-3.4x
P/E 2027 * -3.06x
Enterprise Value 274M 244M 226M 205M 385M 25.98B 392M 2.71B 1.07B 13.6B 1.03B 1.01B 43.37B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 10.7x
Free-Float
99.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+9.17%
1 week+13.49%
Current month-5.26%
1 month-4.39%
3 months-11.87%
6 months+5.52%
Current year+65.18%
1 week 2.59
Extreme 2.59
3.2
1 month 2.59
Extreme 2.59
3.45
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
48.75
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 01/10/2020
Director of Finance/CFO 49 17/09/2023
Chief Tech/Sci/R&D Officer 56 27/10/2024
Director TitleAgeSince
Director/Board Member 74 30/11/2015
Director/Board Member 55 13/09/2020
Director/Board Member 55 15/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Founder

3,662 0.0030%
01/10/26 Free

Director

4,618 0.0038%
18/09/26 Exercice

Chief Financial Officer

9,025 0.0073%
Change 5-day change 1-year change 3-year change Capi.($)
+9.52%+13.49%+24.21%+68.72% 356M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.62%+2.74%+26.30%+45.27% 43.76B
+3.95%+9.96%+20.49%+132.34% 42.09B
+7.78%+4.36%+264.10%+603.07% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +3.70%-0.10%+49.55%+117.56% 37.62B
Weighted average by Cap. +3.05%+0.61%+51.09%+124.39%

Financials

2026 *2027 *
Net sales 26.4M 23.5M 21.78M 19.73M 37.09M 2.5B 37.71M 261M 103M 1.31B 99.02M 96.97M 4.18B 22.29M 19.84M 18.38M 16.66M 31.31M 2.11B 31.83M 221M 86.66M 1.1B 83.59M 81.86M 3.52B
Net income -113M -101M -93.3M -84.55M -159M -10.71B -162M -1.12B -440M -5.61B -424M -415M -17.89B -146M -130M -120M -109M -205M -13.82B -208M -1.44B -567M -7.23B -547M -536M -23.07B
Net Debt -81.29M -72.36M -67.06M -60.77M -114M -7.7B -116M -805M -316M -4.03B -305M -299M -12.86B -117M -104M -96.64M -87.57M -165M -11.1B -167M -1.16B -456M -5.81B -439M -430M -18.53B
Projected Income Statement - Annual - C4 Therapeutics, Inc.
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
20/10/26 US$3.155 +9.17% 3,344,167
19/10/26 US$2.890 +4.52% 3,113,184
16/10/26 US$2.765 -0.54% 2,359,351
15/10/26 US$2.780 +6.51% 3,275,294
14/10/26 US$2.610 -6.12% 3,099,942
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - C4 Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.890USD
Average target price
12.86USD
Spread / Average Target
+344.88%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - C4 Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CCCC Stock